Abbott's Q3 earnings hit by costs
This article was originally published in Scrip
Executive Summary
Abbott Laboratories' net earnings dropped by 40% in the third quarter to $891 million, hit by costs associated with the acquisition of Solvay, higher rebates required under US healthcare reform, a baby formula product recall and sales returns associated with the withdrawal of the diet drug Meridia (sibutramine).